Search

Immobilized enzymes offer different benefits such as the feasibility to be reused for reproducible bioprocesses. The challenge is to establish the appropriate storage conditions that allow the maintenance of their properties for long periods. In this study, we immobilized a recombinant leucine aminopeptidase (I-rLAP) on a siliceous support synthesized from tetraethyl orthosilicate (TEOS) activated with glutaraldehyde to evaluate its residual activity after storage in 20% v/v ethanol and sodium azide solutions at 4 and 25 °C. The characterization of the support by X-ray diffraction (XRD), diffuse reflectance infrared Fourier transform (DRIFT) and field emission probe microanalyzer (EPMA) was consistent with previous characterization reports of silica gel matrices. Particle size ≤420 μm exhibited a suitable performance that avoided high backpressure into the columns and increased the amount of immobilized enzyme. I-rLAP recovered up to 90% of the applied activity after 64 days of storage at 4 and 25 °C in 20% v/v ethanol. Conversely, no effect was observed when the insoluble enzyme was stored in sodium azide. Activity recovery of I-rLAP after storage in ethanol solution could be related to the formation of disulfide bonds as suggested by free thiol analyses. Reverse phase-ultra performance liquid chromatography (RP-UPLC) and Mass Spectrometry confirmed that the immobilized enzyme maintained its specificity to remove N-terminal methionine from a recombinant hormone. The obtained results indicate that this methodology constitutes an alternative for bioprocesses involving long-term storage of immobilized enzymes. [ABSTRACT FROM PUBLISHER]

This work describes a strategy to optimize a downstream processing of a recombinant human growth hormone (rhGH) by incorporating a quality by design approach toward meeting higher quality specifications. The optimized process minimized the presence of impurities and degradation by-products during manufacturing by the establishment of in-process controls. Capillary zone electrophoresis, reverse phase, and size-exclusion chromatographies were used as analytical techniques to establish new critical process parameters for the solubilization, capture, and intermediate purification steps aiming to maintain rhGH quality by complying with pharmacopeial specifications. The results indicated that the implemented improvements in the process allowed the optimization of the specific recovery and purification of rhGH without compromising its quality. In addition, this optimization facilitated the stringent removal of the remaining impurities in further polishing stages, as demonstrated by the analysis of the obtained active pharmaceutical ingredient. [ABSTRACT FROM AUTHOR]